Home » Stocks » PRTC

PureTech Health PLC (PRTC)

Stock Price: $56.80 USD 0.00 (0.00%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 1.53B
Revenue (ttm) 11.77M
Net Income (ttm) 4.57M
Shares Out 285.74M
EPS (ttm) 0.20
PE Ratio 284.00
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $56.80
Previous Close $56.80
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 54.20 - 59.00
Day's Volume 18
52-Week Range 33.00 - 65.90

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, a leading clinical-stage microbiome company developing a new category of oral therapies using rationally defined bacterial consortia manufactured ...

1 week ago - Business Wire

BOSTON--(BUSINESS WIRE)--PureTech Announces Nature Publication Supporting Modulation of Meningeal Lymphatics to Target Alzheimer's Disease Pathologies

1 week ago - Business Wire

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Gelesis Appoints Procter & Gamble Veteran Jane Wildman to Board of Directors

1 week ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, a leading clinical-stage microbiome company developing a new category of oral therapies using rationally defined bacterial consortia manufactured ...

3 weeks ago - Business Wire

BOSTON--(BUSINESS WIRE)--PureTech Announces Annual Results for Year Ended December 31, 2020

3 weeks ago - Business Wire

BOSTON--(BUSINESS WIRE)--PureTech Presents Promising Preclinical Data from LYT-210 Immuno-Oncology Program at American Association for Cancer Research (AACR) Annual Meeting

3 weeks ago - Business Wire

BOSTON--(BUSINESS WIRE)--PureTech to Present at Two Upcoming Investor Conferences

1 month ago - Business Wire

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing hi...

1 month ago - Business Wire

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Akili Announces the Results of EndeavorRx™ Clinical Study in Pediatric ADHD Published in Nature Digital Medicine

1 month ago - Business Wire

BOSTON--(BUSINESS WIRE)--PureTech announces Stephen Muniz, Esq., will retire from his role as Chief Operating Officer and will step down from the Board Of Directors.

1 month ago - Business Wire

BOSTON--(BUSINESS WIRE)--Notice of Results

1 month ago - Business Wire

BOSTON--(BUSINESS WIRE)--PureTech to Present at The Barclays Global Healthcare Conference

2 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, a leading clinical-stage microbiome company developing a new category of oral therapies using rationally defined bacterial consortia manufactured ...

2 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--PureTech Announces Publication of Glyph Platform Preclinical Proof-of-Concept Study in Journal of Controlled Release

2 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing hi...

Other stocks mentioned: KRTX
2 months ago - Business Wire

Keep in mind downside risk, if their respective candidates fail to pan out. But, there may be opportunity with these seven biotech stocks targeting treatments for long-haul Covid-19.

Other stocks mentioned: AIM, CDMO, CYDY, FLGT, HGEN, JAGX
2 months ago - InvestorPlace

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Vor Biopharma Closes Over $200M Initial Public Offering

2 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Vedanta announces $25 million investment from Pfizer Inc. as part of the Pfizer Breakthrough Growth Initiative.

3 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta announces $25 million investment from Pfizer Inc. as part of the Pfizer Breakthrough Growth Initiative.

3 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--PureTech (Nasdaq: PRTC) initiated a global, Phase 2 trial of LYT-100 (deupirfenidone) in Long COVID respiratory complications and related sequelae.

5 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Vedanta Biosciences Appoints Troy Ignelzi, Chief Financial Officer at Karuna Therapeutics, to its Board of Directors

5 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences Appoints Troy Ignelzi, Chief Financial Officer at Karuna Therapeutics, to its Board of Directors

5 months ago - Business Wire

About PRTC

PureTech Health plc, a clinical stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and dementia-related psychosis; a hydrogel platform technology to treat obesity and other chronic metabolic diseases; a regenerative biology platform for androgenetic ... [Read more...]

Industry
Biotechnology
CEO
Daphne Zohar
Employees
250
Stock Exchange
NASDAQ
Ticker Symbol
PRTC
Full Company Profile

Financial Performance

In 2020, PRTC's revenue was $11.77 million, an increase of 20.00% compared to the previous year's $9.81 million. Earnings were $4.57 million, a decrease of -98.75%.

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for PRTC is 73.50, which is an increase of 29.40% from the latest price.

Price Target
$73.50
(29.40% upside)